Vectus Biosystems Ltd (VBS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vectus Biosystems Ltd (VBS) has a cash flow conversion efficiency ratio of 2.572x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-659.98K ≈ $-466.98K USD) by net assets (AU$-256.62K ≈ $-181.58K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vectus Biosystems Ltd (VBS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Vectus Biosystems Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vectus Biosystems Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vectus Biosystems Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RH Bophelo Ltd
JSE:RHB
|
-0.003x |
|
Metal Hawk Ltd
AU:MHK
|
-0.079x |
|
AIxCrypto Holdings, Inc.
NASDAQ:AIXC
|
-0.056x |
|
Oscar Mitra Sukses Sejahtera Tbk PT
JK:OLIV
|
0.061x |
|
CASA DE BUCOVINA-CLUB DE MUNTE
RO:BCM
|
-0.009x |
|
Ahlada Engineers Limited
NSE:AHLADA
|
0.024x |
|
Volato Group Inc.
NYSE MKT:SOAR
|
-3.163x |
|
Processa Pharmaceuticals Inc
NASDAQ:PCSA
|
-0.520x |
Annual Cash Flow Conversion Efficiency for Vectus Biosystems Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Vectus Biosystems Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Vectus Biosystems Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-256.62K ≈ $-181.58K |
AU$-830.09K ≈ $-587.34K |
3.235x | +336.52% |
| 2024-06-30 | AU$1.49 Million ≈ $1.05 Million |
AU$-2.03 Million ≈ $-1.44 Million |
-1.368x | -104.82% |
| 2023-06-30 | AU$3.52 Million ≈ $2.49 Million |
AU$-2.35 Million ≈ $-1.66 Million |
-0.668x | -166.48% |
| 2022-06-30 | AU$-4.42 Million ≈ $-3.13 Million |
AU$-4.44 Million ≈ $-3.14 Million |
1.004x | -10.54% |
| 2021-06-30 | AU$-2.90 Million ≈ $-2.05 Million |
AU$-3.26 Million ≈ $-2.30 Million |
1.123x | +151.03% |
| 2020-06-30 | AU$-6.71 Million ≈ $-4.75 Million |
AU$-3.00 Million ≈ $-2.12 Million |
0.447x | +60.32% |
| 2019-06-30 | AU$-3.73 Million ≈ $-2.64 Million |
AU$-1.04 Million ≈ $-736.30K |
0.279x | -54.62% |
| 2018-06-30 | AU$-2.26 Million ≈ $-1.60 Million |
AU$-1.39 Million ≈ $-981.46K |
0.615x | +101.84% |
| 2017-06-30 | AU$116.56K ≈ $82.48K |
AU$-3.89 Million ≈ $-2.75 Million |
-33.399x | -4696.01% |
| 2016-06-30 | AU$3.75 Million ≈ $2.65 Million |
AU$-2.61 Million ≈ $-1.85 Million |
-0.696x | -376.09% |
| 2015-06-30 | AU$11.22 Million ≈ $7.94 Million |
AU$-1.64 Million ≈ $-1.16 Million |
-0.146x | +99.37% |
| 2014-06-30 | AU$55.53K ≈ $39.29K |
AU$-1.29 Million ≈ $-915.18K |
-23.292x | -1926.15% |
| 2013-06-30 | AU$976.04K ≈ $690.61K |
AU$-1.12 Million ≈ $-793.92K |
-1.150x | -141.21% |
| 2012-06-30 | AU$-504.57K ≈ $-357.02K |
AU$-1.41 Million ≈ $-995.86K |
2.789x | -- |
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more